ENDRA Life Sciences (NDRA) Total Current Liabilities (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Total Current Liabilities for 11 consecutive years, with $786578.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 36.41% year-over-year to $786578.0 in Q2 2026; TTM through Jun 2026 was $786578.0, a 36.41% increase from a year earlier, with the FY2025 full-year figure at $750956.0, up 24.08% from the prior year.
• Total Current Liabilities was $786578.0 for Q2 2026 at ENDRA Life Sciences, down from $835440.0 in the prior quarter.
• Over five years, Total Current Liabilities peaked at $2.2 million in Q3 2023 and troughed at $565785.0 in Q1 2025.
• A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 77.32% in 2022 and plunged 62.48% in 2024, its largest moves.
• Over 5 years, Total Current Liabilities stood at $1.7 million in 2022, then tumbled by 46.99% to $903095.0 in 2023, then tumbled by 32.98% to $605230.0 in 2024, then climbed by 24.08% to $750956.0 in 2025, then gained by 4.74% to $786578.0 in 2026.
• The last three Total Current Liabilities figures came in at $786578.0 (Q2 2026), $835440.0 (Q1 2026), and $750956.0 (Q4 2025), per Business Quant data.